Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1243-1251

  O'Farrell, Sean ^a,b   Garmo, Hans ^a,c   Holmberg, Lars ^a,c,d   Adolfsson, Jan ^d,e   Stattin, Pär ^f   Van Hemelrijck, Mieke ^a,e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c Regional Cancer Centre   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROSTOMY; ORCHIECTOMY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; TRANSURETHRAL RESECTION; TREATMENT DURATION; VERY ELDERLY; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CHEMICALLY INDUCED; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; REGISTER; RISK ASSESSMENT; RISK FACTOR; SWEDEN; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORCHIECTOMY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927151847     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.1792     Document Type: Conference Paper

References (44)

1. Heidenreich A, Aus G, Bolla M, et al: EAU guidelines on prostate cancer. Eur Urol 53:68-80, 2008
2. Hsing AW, Chokkalingam AP: Prostate cancer epidemiology. Front Biosci 11:1388-1413, 2006
3. Widmark A, Klepp O, Solberg A, et al: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 373:301-308, 2009
4. Saylor PJ, Smith MR: Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181:1998-2006, 2009
5. Saylor PJ, Smith MR: Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 189:S34-S42, 2013 (suppl 1)
6. Albini A, Pennesi G, Donatelli F, et al: Cardiotoxicity of anticancer drugs: The need for cardiooncology and cardio-oncological prevention. J Natl Cancer Inst 102:14-25, 2010
7. Efstathiou JA, Bae K, Shipley WU, et al: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 54:816-823, 2008
8. Hanks GE, Pajak TF, Porter A, et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972-3978, 2003
9. Hayes JH, Chen MH, Moran BJ, et al: Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 106:979-985, 2010
10. Jespersen CG, Nørgaard M, Borre M: Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: A nationwide Danish population-based cohort study. Eur Urol 65:704-709, 2014
11. Keating NL, O'Malley A, Freedland SJ, et al: Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 104: 1518-1523, 2012
12. Martín-Merino E, Johansson S, Morris T, et al: Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: A nested case-control study in UK primary care. Drug Saf 34:1061-1077, 2011
13. Robinson D, Garmo H, Lindahl B, et al: Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. Int J Cancer 130:478-487, 2012
14. Saigal CS, Gore JL, Krupski TL, et al: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110: 1493-1500, 2007
15. Tsai HK, D'Amico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007
16. Van Hemelrijck M, Garmo H, Holmberg L, et al: Absolute and relative risk of cardiovascular disease in men with prostate cancer: Results from the population-Based PCBaSe Sweden. J Clin Oncol 28:3448-3456, 2010
17. Yeh ET, Bickford CL: Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53: 2231-2247, 2009
18. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456, 2006
19. US Food and Drug Administration: FDA drug safety communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GNRH agonists to add new safety information to labelling regarding increased risk of diabetes and certain cardiovascular diseases. http:// www.fda.gov/Drugs/DrugSafety/ucm229986.htm
20. Bourke L, Kirkbride P, Hooper R, et al: Endocrine therapy in prostate cancer: Time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer 108:9-13, 2013
21. Nguyen PL, Chen MH, Hoffman KE, et al: Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int 110: 201-205, 2012
22. Schroder F, Crawford ED, Axcrona K, et al: Androgen deprivation therapy: Past, present and future. BJU Int 109:1-12, 2012 (suppl 6)
23. Schulman C, Irani J, Aapro M: Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy. BJU Int 109:13-21, 2012 (suppl 6)
24. Nguyen PL, Je Y, Schutz FA, et al: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A metaanalysis of randomized trials. JAMA 306:2359-2366, 2011
25. Van Hemelrijck M, Wigertz A, Sandin F, et al: Cohort profile: The National Prostate Cancer Register of Sweden and Prostate Cancer Data Base Sweden 2.0. Int J Epidemiol 42:956-967, 2013
26. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
27. Wettermark B, Hammar N, Fored CM, et al: The new Swedish Prescribed Drug Register: Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726-735, 2007
28. National Comprehensive Cancer Network: National Comprehensive Cancer Network Guidelines 2012. http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp
29. Trump DL: Commentary on "association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A metaanalysis of randomized trials." Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK, Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA: JAMA 2011;306(21):2359-66.
30. Urol Oncol 30: 746-747, 2012
31. Nanda A, Chen MH, Braccioforte MH, et al: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302:866-873, 2009
32. Albertsen PC, Klotz L, Tombal B, et al: Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565-573, 2014
33. Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 7:165-170, 1988
34. Henriksson P, Edhag O, Eriksson A, et al: Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer. Br J Urol 63:186-190, 1989
35. Henriksson P, Johansson SE: Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. Am J Epidemiol 125:970-978, 1987
36. Lundgren R, Sundin T, Colleen S, et al: Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma: A preliminary report from a randomized multicenter study. Scand J Urol Nephrol 20:101-105, 1986
37. Mikkola AK, Ruutu ML, Aro JL, et al: Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer: Efficacy and cardiovascular complications-A 2-year follow-up report of a national, prospective prostatic cancer study: Finnprostate Group. Br J Urol 82:63-68, 1998
38. Nguyen PL: Androgen-deprivation therapy and cardiovascular harm: Let's not throw out the baby with the bathwater. Eur Urol 65:710-712, 2014
39. Chen HF, Jeung EB, Stephenson M, et al: Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 84:743-750, 1999
40. Jacobson JD, Nisula BC, Steinberg AD: Modulation of the expression of murine lupus by gonadotropin-releasing hormone analogs. Endocrinology 134:2516-2523, 1994
41. Tanriverdi F, Gonzalez-Martinez D, Hu Y, et al: GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 142:103-110, 2005
42. Dockery F, Bulpitt CJ, Agarwal S, et al: Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195-201, 2003
43. Giovannucci E, Rimm EB, Ascherio A, et al: Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev 8:277-282, 1999
44. Keating NL, O'Malley AJ, Freedland SJ, et al: Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64:159-166, 2013